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Abstract 
Purpose 
Variations in proton Relative Biological Effectiveness (RBE) with Linear Energy Transfer (LET) remain 
one of the largest sources of uncertainty in proton radiotherapy. This work seeks to identify physics-
based metrics which can be applied to reduce this biological uncertainty. 
Materials and Methods 
Three different physical metrics – dose, dose × LET and a complexity-weighted dose (CWD, 𝐷𝑜𝑠𝑒 ×
(1 + 𝜅 𝐿𝐸𝑇𝐷) ) were compared with in vitro experimental studies of proton RBE and clinical 
treatment plans analysed using RBE models. The biological effects of protons in each system were 
plotted against these metrics to quantify the degree of biological uncertainty introduced by RBE 
variations in each case.  
Results 
When the biological effects of protons were plotted against dose alone, significant biological 
uncertainty was introduced as the LET-dependence of RBE was neglected. Plotting biological effects 
against dose × LET significantly over-estimated the impact of LET on cell survival, leading to similar or 
greater levels of biological uncertainty. CWD, by contrast, significantly reduced biological 
uncertainties in both experiments and clinical plans. For prostate and medulloblastoma treatment 
plans, biological uncertainties were reduced from ±5% to less than 1%.   
Conclusions 
While not a replacement for full RBE models, physics-based metrics such as CWD have the potential 
to significantly reduce the uncertainties in proton planning which result from variations in RBE. 
These metrics may be used to identify regions in normal tissues which may see unexpectedly high 
effects due to end-of-range elevations of RBE, or as a tool in optimisation to deliver uniform 
biological effects.  
 
  
Introduction 
Proton radiotherapy offers significant dosimetric advantages over conventional photon-based 
therapies, as proton’s continuous energy loss gives them a well-defined range with greatest energy 
deposition at the end of their path. As a result, normal tissue doses can be significantly reduced, 
reducing side-effects or allowing an escalation of target doses [1]. 
However, using protons is not problem-free. Protons bring new challenges in dosimetry and 
planning, as uncertainties in the tissue composition and particle range can lead to classes of 
uncertainty not seen in photon radiotherapy [2,3]. But perhaps more significantly, there are also 
differences in biological effectiveness between photons and protons which are not typically 
incorporated in clinical planning. 
When different particles are used to deliver the same dose of ionising radiation, differences in 
biological effects are observed, typically defined in terms of a Relative Biological Effectiveness (RBE) 
– the ratio between the dose needed to produce a particular biological response with the test 
radiation and the dose of a reference radiation which produces the same effect. For protons, a 
constant RBE of 1.1 is typically assumed, and plans are optimised based on physical dose alone [4].  
While this reflects that protons are more biologically effective than photons, it assumes that this 
effect is a constant independent of dose, tissue type and LET, despite extensive preclinical evidence 
that proton RBEs are variable. This reflects a significant limitation in proton treatment planning, as it 
introduces large biological uncertainties into planning, which can be many times larger than 
acceptable limits for physical uncertainty. As a result, proton therapy is not delivering on its full 
potential. Incorporation of the LET-dependence of proton RBE could reduce treatment uncertainties 
and potentially identify RBE ‘hotspots’ which may drive unexpectedly large responses, particularly at 
the end of range which typically occurs in normal tissue [5]. 
Empirical analytic proton RBE models have been developed to better understand and quantify these 
effects. Typically, these models begin from the linear-quadratic cell survival model, and adjust the α 
and β parameters with the introduction of LET-dependent terms [6–8]. While these models broadly 
agree on overall trends in proton RBE for cell survival, they have seen limited translation to the 
clinic. In part, this is because these models depend on both the α/β ratio of the target tissue as well 
as model-specific fitting parameters which carry significant uncertainties and potential inter-patient 
variability, which translates into significant uncertainties in predicted RBE [9–11]. Furthermore, 
these models are based on cell survival endpoints that may not be relevant for normal tissue 
toxicities. 
But it is important to note that even in photon-based therapy treatments are planned based on 
physical dose rather than biological effect, and there is considerable biological uncertainty around 
the effects of a given dose – both between different tissues and between different patients [12–14]. 
Despite this, dose-based planning is effective because tissue response is monotonic with dose: 
increasing dose smoothly and continuously increases effect, even if the exact level of cell killing is 
unknown. 
Similar ideas can be applied in proton therapy – even if there remains significant uncertainties in 
RBE, physically-determined metrics which correlate better with response have the potential to serve 
as useful tools for treatment optimisation. In this vein, groups have proposed optimisations based 
on the physical quantities of dose and LET as a proxy for response, rather than RBE models [15–18]. 
However, it remains unclear how effectively these approaches reduce biological uncertainties, or 
what metric is best suited to this purpose. In this work, we evaluate dose, dose × LET and a weighted 
average of these quantities to evaluate how effectively they can be used to reduce RBE-related 
biological uncertainties.  
Methods 
Radiation Response Metrics and Biological Uncertainty 
When cells are exposed to a given proton dose, a range of survivals may be observed due to the LET-
RBE relationship whose biology is not described by dose alone. In this work, this range of responses 
seen for a given dose (or other response metric) is referred to as the ‘biological uncertainty’.  
Three response metrics have been studied: physical dose, 𝐷; dose-LET product, 𝐷 × 𝐿𝐸𝑇𝐷; and a 
weighted average of these metrics, called Complexity Weighted Dose (CWD) given by 𝐷𝐶𝑊 = 𝐷 +
𝜅 𝐷 ×  𝐿𝐸𝑇𝐷 = 𝐷 × (1 + 𝜅 𝐿𝐸𝑇𝐷), where 𝜅 is an empirical fitting parameter with units of μm/keV. 
While this approach can potentially be applied to either track- or dose-averaged LET, within the 
work we have focused on dose-averaged LET (𝐿𝐸𝑇𝐷). 
Cell Survival Data 
Survival data for cells exposed to protons was obtained from previous publications for AGO-1522 
fibroblasts and U87 glioma cells [19,20]. Clonogenic cell survival was measured at various positions 
across either pristine or spread-out Bragg peaks (SOBPs) to quantify the dose response curves at 
different energies, with doses from 0 to 7 Gy and 𝐿𝐸𝑇𝐷 from 0 to 25 keV/μm. For each position, 
𝐿𝐸𝑇𝐷 was calculated using Monte Carlo simulations of the beamline using Geant4 [21]. Further 
details on experimental design can be found in the original papers [19,20].  
Survival from these experiments was then plotted against each of the three candidate metrics. 
Correlation between each metric and biological response was assessed by fitting a function of the 
form ln(𝑆) = −𝐴𝑀 − 𝐵𝑀2, where 𝑀 is one of the three metrics, and 𝐴 and 𝐵 are fitting 
parameters.  
For 𝑀 = 𝐷, this reduces to the standard linear-quadratic dose response model with 𝐴 and 𝐵 taking 
units of Gy-1 and Gy-2. These units are also used for complexity weighted dose. For the 𝑀 = 𝐷 𝐿𝐸𝑇𝐷 
case, A and B take units of μm keV-1 Gy-1 and um2 keV-2 Gy-2, respectively. While the dose-LET 
product can be rescaled to units of Gy by multiplying by a 𝜅-like term, this does not impact on the 
overall correlation and so was not done.  
Spread Out Bragg Peak RBE Comparison 
Experimental data necessarily covers only a limited range of combinations of dose and 𝐿𝐸𝑇𝐷. To 
evaluate the metrics at a wider range of conditions and to better understand their underlying 
behaviour in this experimental dataset, RBE was modelled analytically across the whole SOBP. Dose 
and 𝐿𝐸𝑇𝐷 distributions were calculated for a 2 Gy SOBP delivered with 62 MeV protons with 10 mm 
range modulation, corresponding to that used experimentally [19].  
At each point along the SOBP, RBE-weighted doses were calculated based on experimentally-
determined parameters, with survival given by: 
𝑆 = 𝑒−(𝛼𝑥+𝜆𝐿𝐸𝑇𝐷)𝐷−𝛽𝑥𝐷
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Where 𝛼𝑥 and 𝛽𝑥 are the experimentally-determined X-ray radiosensitivity parameters, and 𝜆 is an 
empirical fitting parameter describing the LET dependence of 𝛼 for protons. For these experiments 
[19,20], these parameters were determined to be: 𝛼 = 0.77 ± 0.02 Gy-1, 𝛽 = 0.06 ± 0.01 Gy-2 and 
𝜆 = 0.06 ± 0.01 Gy-1 μm keV-1 for AGO-1522 cells; and 𝛼 = 0.13 ± 0.02 Gy-1, 𝛽 = 0.05 ± 0.02 Gy-2 
and 𝜆 = 0.026 ± 0.003 Gy-1 μm keV-1 for U87 cells. These RBE-weighted doses were then plotted 
against each of the three metrics.  
Clinical Treatment Plan Comparison 
Finally, two realistic clinical treatment plans were evaluated: one medulloblastoma and one 
prostate. Clinically delivered treatment plans were re-simulated using TOPAS [22] as described 
elsewhere [8] to provide dose and 𝐿𝐸𝑇𝐷 distributions for the plans.  
As specific survival data is not available for the tissues in these treatment plans, RBEs were 
calculated using a previously published phenomenological model [8]. This model includes tissue α/β 
ratios and four empirical model parameters which were fit to published experimental data. RBE-
weighted doses were then calculated for each plan, with α/β values set to 10 for the 
medulloblastoma, 1.5 for the prostate, and 3 for all normal tissues. RBE-weighted doses were then 
compared to each of the three response metrics for all voxels seeing at least 1% of the prescription 
dose.  
Statistical Analysis 
A single value of 𝜅 was used throughout this work for all endpoints and cell types. This value was 
obtained by carrying out least-squares fitting to the experimental survival data in both cell lines as 
presented in Figure 1 c and f. 
Results 
Cell Survival 
Experimental cell survival values are plotted against each of the response metrics in Figure 1 for 
AGO-1522 and U87 cells. Plotting against dose alone (a, d) shows the well-established LET 
dependence of proton RBE, with an average fit over-estimating cell killing at low LET and under-
estimating cell killing at high LET. This leads to a significant biological uncertainty at all doses.  
When considering 𝐷 × 𝐿𝐸𝑇𝐷 (b, e), this trend is reversed, with the average fit under-estimating 
killing at low LET, and over-estimating at high LET, with a significantly greater biological uncertainty 
than seen for dose alone. This highlights that 𝐷 × 𝐿𝐸𝑇𝐷 alone is not a useful metric for biological 
response, but the trend is in line with suggestions that it is a proxy for additional biological effect, 
suggesting that a combined metric may be useful. 
This combined metric, the complexity-weighted dose, 𝐷𝐶𝑊 = 𝐷 × (1 + 𝜅 𝐿𝐸𝑇𝐷), is plotted in the 
lower panels (c,f), with a fitted 𝜅 = 0.055 ± 0.003, showing significantly improved correlation. 𝑅2 
values were 0.84 and 0.88 for AGO-1522 and U87 cells when fit using dose alone, increasing to 0.99 
and 0.95 when fit using CWD. Applying CWD with a single κ parameter thus accounts for 60 to 90% 
of the LET-related uncertainty in survival in these cells, despite the different overall radiosensitivities 
and X-ray 𝛼/𝛽 ratios of these cell lines (12 Gy and 2.5 Gy).  
Spread Out Bragg Peak RBE 
Figure 2 presents dose and 𝐿𝐸𝑇𝐷 distributions across a 2 Gy SOBP delivered using 62 MeV protons 
with a 10 mm range modulation, together with RBE-weighted doses for AGO-1522 and U87 cells 
using empirical fitting to the experimental data in Figure 1. 
For each position along the depth-dose curve, RBE-weighted doses were compared to the different 
dose metrics, shown in Figure 3. Comparing dose alone to RBE-weighted dose shows similar trends 
to survival, under-estimating the effects of high LET exposures (a, d). In these plots, trends across the 
SOBP can be observed – initially, there is good correlation with dose in the low-LET entrance region 
(dark points) where RBE variations are small. But within the SOBP, dose is roughly constant while LET 
and RBE increase significantly. And then in the distal tail, dose falls steeply while RBE continues to 
increase, giving rise to a wide spread in possible biological effects at a given dose. 
A similar spread is seen comparing with 𝐷 × 𝐿𝐸𝑇𝐷, although once again the trends with LET are 
reversed (b, e). An initially rapid rise is seen as dose increases, but within the SOBP the slope is much 
shallower, as the dependence of RBE-weighted dose on LET is much less than its dependence on 
physical dose. This also leads to a significant over-estimation of effect in the distal tail.  
Applying CWD using 𝜅 = 0.055 dramatically reduces biological uncertainties (c, f), as both physical 
dose and LET are appropriately taken into account. In both cases uncertainties are substantially 
reduced, with overall performance slightly better in AGO-1522 than in U87 cells. It is important to 
note that these plots show some curvature rather than the direct proportionality which would be 
expected of a ‘true’ RBE model, as CWD deliberately does not seek to take into account differences 
in the underlying tissue biology. However, by providing a monotonic correlation with effect, it can 
effectively identify regions of high biological effect for use in treatment design or optimisation. 
Clinical Treatment Plans  
Finally, these effects have been calculated for medulloblastoma and prostate clinical treatment 
plans, with dose and 𝐿𝐸𝑇𝐷 distributions shown in Figure 4. In common with most proton treatment 
plans, these approaches have relatively low LETs in the entrance region and much of the target 
volume, but higher LETs at the end of range and at edges of treatment fields. For each voxel in the 
treatment plan, an RBE-weighted dose has been calculated using the model of McNamara et al [8]  
and compared against each of the three response metrics, plotted in Figure 5.  
Comparing dose alone (a, d) to RBE-weighted dose illustrates the range of biological uncertainty in 
these plans if they are optimised on physical dose as is currently the case. There is significant 
variation across the whole dose range, equivalent to ±5% of the prescription dose or more. This is 
again due to the lack of incorporation of RBE variability, with higher LET regions seeing increased 
biological effects. 𝐷 × 𝐿𝐸𝑇𝐷(b, e) is ineffective at resolving this uncertainty, over-estimating the 
impact of LET and introducing new biological uncertainties. 
However, the weighted dose metric (c, f) greatly reduces this biological uncertainty. By applying the 
same 𝜅 = 0.055 as in the experimental dataset, biological uncertainties can be reduced to less than 
1% across the whole dose range. This suggests that this approach may effectively help to identify 
regions of high biological effect in treatment planning and optimisation. 
Sensitivity to κ 
A single value of 𝜅 = 0.055 has been used throughout this work, determined by minimising the 
biological uncertainties in an initial in vitro experimental dataset. To evaluate the sensitivity of this 
model parameter, we calculated the average biological uncertainty across the two clinical plans for a 
range of values of κ and 𝛼/𝛽. Biological uncertainty was defined as the 95% confidence interval of 
biological effect, plotted in Figure 6.  
In the limit of 𝜅 = 0, this gives the biological uncertainty according to dose alone, which is 
approximately ±5% for a normal tissue α/β of 3 Gy as shown in Figure 5. As κ increases, these 
uncertainties decrease, reaching a minimum of less than 1% around 𝜅 = 0.055. This minimum is 
relatively shallow, with κ values from 0.04 to 0.08 all yielding average biological uncertainties less 
than 1.5%, suggesting that this metric still offers good improvements in predictive power even if the 
κ value is not precisely optimised. A shaded range is also plotted showing the range of biological 
uncertainties for 𝛼/𝛽 ratios from 2 to 10 Gy. While the exact degree of uncertainty varies 
considerably depending on the tissue 𝛼/𝛽, 𝜅 = 0.055 also provides a minimisation of the worst-case 
error.  
Discussion 
Fully optimising treatment plans remains a significant challenge in radiotherapy, particularly in 
proton therapy where the LET dependence of biological response adds extra potential dimensions of 
optimisation [23]. However, despite extensive evidence that proton RBE is variable, most clinical 
approaches adopt the conservative approach of a constant RBE of 1.1 [3]. 
In this work, we explored the use of physics-based metrics to reduce the biological uncertainties in 
radiation response. In particular, we sought to identify metrics which were monotonically related to 
survival, without explicitly calculating RBE values. By not attempting to generate equivalent photon 
doses, many aspects of the underlying biology which are subject to large uncertainties (such 
underlying tissue radiosensitivity and α/β ratio) can be neglected, greatly simplifying this calculation. 
Despite this simplification, we find that CWD significantly reduces uncertainty in level of response 
when compared to dose or 𝐷𝑜𝑠𝑒 ×  𝐿𝐸𝑇𝐷 alone, reducing uncertainty from ±5% to ±1% in clinical 
treatment plans.  
Such an approach has significant potential for applications in proton therapy. A major ongoing area 
of research is in optimising therapy to account for elevated end-of-range LETs in normal tissue which 
may lead to increased complication rates [24]. This metric can help guide such studies by identifying 
regions would be expected to show the greatest deviation from physical dose alone. In addition, 
while optimising dose and LET independently may go some way to addressing RBE effects [17,18], 
because of the interplay between these parameters it is possible that reduction in physical dose will 
be offset by increases in LET, or vice-versa. By reducing this uncertainty, optimisation of complexity-
weighted dose has the potential to offer more biologically robust solutions [3]. 
It is important to note that this approach is not a true RBE model. The relationship between CWD 
and RBE-weighted dose (Figures 3 & 5), because variations in tissue sensitivity and α/β are not taken 
into account. This also means that these curves will be different for different tissues – as can be seen 
in Figure 5, where separate small clusters of points are seen at high doses, corresponding to tumour 
volumes with different α/β ratios to normal tissue (a higher α/β value leading to lower RBEs in the 
medulloblastoma case, and vice versa for prostate). However correlations remain good within a 
given tissue, enabling robust optimisation of effects as in photon therapy.  
Finally, this work, a value of 𝜅 = 0.055 has been used based on in vitro experimental data, which 
was seen to perform well across the range of scenarios considered here and may already be an 
effective tool in optimising therapy. However, as this approach is necessarily an approximation to 
the true underlying biology, the true optimum value will depend on the chosen target, tissue α/β 
ratios, and the dose and 𝐿𝐸𝑇𝐷 characteristics of the treatment plan. More comprehensive planning 
and analysis studies are needed to fully assess the performance of this model in a range of scenarios 
and what impact these choices may have on the clinic. 
Conclusions 
A complexity-weighted dose (CWD) metric, 𝐷𝐶𝑊 = 𝐷 ×  (1 + 𝜅 𝐿𝐸𝑇𝐷), has been found to effectively 
reduce biological uncertainties resulting from variable RBE in proton radiotherapy. While this cannot 
be used to set absolute dose constraints, it effectively identifies regions which may see elevated 
biological effects due to high LET, and may prove a valuable tool for therapy optimisation and 
retrospective response analysis. 
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 Figure 1: Uncertainty in cell survival compared to different response metrics for AGO-1522 fibroblast 
(left) and U87 glioma (right) cells[19,20]. Each point represents a single condition, coloured 
according to LET. When survival is plotted against dose (top), the LET-dependence of proton RBE is 
seen, with increasing cell kill at higher LET. Plotting against 𝐷 × 𝐿𝐸𝑇𝐷 (middle) sees greater 
biological uncertainty, although with a reversed LET dependence. Plotting against CWD (bottom), 
however, gives excellent correlation across all LETs, greatly reducing biological uncertainties.  
  
 Figure 2: Dose and 𝐿𝐸𝑇𝐷 across 62 MeV SOBP with 10 mm modulation, along with RBE-weighted 
doses for two cell lines based on empirical fitting to data in Figure 1.  
  
 Figure 3: Correlation between RBE-weighted dose and response metrics across a SOBP in AGO-1522 
and U87 cells. Each point represents a 0.1 mm slice of the SOBP, coloured according to LET. For dose 
alone (top), there is a significant biological uncertainty due to variations in LET, under-estimating 
effects in high LET regions. As in cell survival, this trend is reversed when considering 𝐷 ×
𝐿𝐸𝑇𝐷 (middle), but the total biological uncertainty is comparable. However, the weighted-dose 
metric (bottom) greatly reduces this uncertainty in both cell lines.  
  
 Figure 4: Dose (top) and 𝐿𝐸𝑇𝐷 (bottom) distributions for prostate (left) and medulloblastoma (right) 
treatment plans. Both plans deliver a range of doses and LETs delivered using different beam 
geometries, and have been analysed to explore spatial variations in RBE-weighted dose with other 
metrics.   
  
 Figure 5: Comparison between RBE-weighted dose and metrics in clinical plans for prostate (left) and 
medulloblastoma (right). Point clouds have been plotted for each voxel receiving more than 1% of 
the prescription dose, coloured according to 𝐿𝐸𝑇𝐷. Dose alone (top) shows the biological variation 
inherent in clinical plans, with voxels assumed to see the same biological effect showing a variation 
equivalent to ±5% of the prescription dose, with high 𝐿𝐸𝑇𝐷 points seeing higher effects. 𝐷 × 𝐿𝐸𝑇𝐷 
(middle) reverses this trend, but shows a much broader range of biological uncertainty. CWD 
(bottom) resolves much of this biological uncertainty, with voxels of a given CWD having a very small 
spread in RBE-weighted dose.  
  
 Figure 6: Average biological uncertainty in both treatment plans as a function of κ, for tissues with 
𝛼/𝛽 values between 2 and 10 Gy. Points represents average response across all 𝛼/𝛽 values, while 
shaded region indicates full range. For 𝜅 = 0 this represents the uncertainty associated with using 
dose alone, and decreases to a minimum of approximately 1% around the 𝜅 = 0.055 used in this 
work.  
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